NOTICE OF MEETING

The shareholders of the company are hereby invited to attend the Combined Ordinary and Extraordinary General Meeting of Shareholders to be held at **8:30 a.m. on June 22, 2018**, at the registered office: 177-181 avenue Pierre Brossolette – 92120 Montrouge, France, to deliberate on the following agenda:

**Ordinary resolutions:**

1. Approval of the annual financial statements for the year ended December 31, 2017.
2. Approval of the consolidated financial statements for the year ended December 31, 2017.
3. Allocation of income for the year.
4. Special report by the Statutory Auditors on regulated agreements and commitments and approval of said agreements.
5. Renewal of the term as Director of Ms. Maïlys FERRERE.
6. Renewal of the term as Director of Ms. Claire GIRAUT.
7. Renewal of the term as Director of Mr. Pierre-Henri BENHAMOU.
8. Renewal of the term as Director of Mr. Michael GOLLER.
9. Renewal of the term as Director of Mr. Torbjorn BJERKE.
10. Renewal of the term as Director of Mr. Daniel SOLAND.
11. Ratification of the provisional appointment as Director of Mr. Michel DE ROSEN.
12. Renewal of the term as Director of Mr. Michel DE ROSEN.
13. Approval of the fixed, variable and extraordinary compensation components and benefits of all types paid or assigned during the year ended to Mr. Pierre-Henri BENHAMOU as Chairman and Chief Executive Officer.
14. Approval of the fixed, variable and extraordinary compensation components and benefits of all types paid or assigned during the year ended to Mr. David SCHILANSKY as Executive Vice President.
15. Approval of the fixed, variable and extraordinary compensation components and benefits of all types paid or assigned during the year ended to Mr. Laurent MARTIN as Executive Vice President.
16. Approval of the principles and criteria for the determination, distribution and allocation of the fixed, variable and extraordinary compensation components and benefits of all types to the Chairman and Chief Executive Officer.
17. Approval of the principles and criteria for the determination, distribution and allocation of the fixed, variable and extraordinary compensation components and benefits of any kind to be attributed to the Executive Vice President / Chief Financial Officer.
18. Approval of the principles and criteria for the determination, distribution and allocation of the fixed, variable and extraordinary compensation components and benefits of all types to the
Executive Vice President / Responsible Pharmacist.

19. Authorization to be granted to the Board of Directors for the Company to buy back its own shares pursuant to Article L. 225-209 of the French Commercial Code, duration of authorization, purpose, conditions, and maximum amount, suspension during public offering period.

Extraordinary resolutions:

20. Delegation of powers to be granted to the Board of Directors to increase the share capital by incorporation of reserves, profits and/or premiums, duration of the delegation, maximum par value amount of the capital increase, handling of fractions, suspension during public offering period.

21. Delegation of powers to be granted to the Board of Directors to issue ordinary shares, giving, as necessary, access to ordinary shares or to the allocation of debt securities and/or securities giving access to ordinary shares with pre-emptive rights, duration of delegation, maximum par value amount of the capital increase, option to offer non-subscribed shares to the public, suspension during public offering period.

22. Delegation of powers to be granted to the Board of Directors to issue ordinary shares, giving, as necessary, access to ordinary shares and/or to the allocation of debt securities and/or securities giving access to ordinary shares, without pre-emptive rights and/or in consideration of securities granted as part of a public exchange offer, duration of the authorization, maximum par value of the capital increase, issue price, option to limit the total amount of subscriptions or redistribute non-subscribed securities, suspension during public offering period.

23. Delegation of powers to be granted to the Board of Directors to issue ordinary shares, giving, as necessary, access to ordinary shares and/or to the allocation of debt securities and/or securities giving access to ordinary shares, without pre-emptive rights by an offering covered by paragraph II of Article L.411-2 of the French Monetary and Financial Code, duration of the authorization, maximum par value amount of the capital increase, issue price, option to limit the total amount of subscriptions or redistribute non-subscribed securities, suspension during public offering period.

24. Authorization, in the event of issue without pre-emptive rights, to set the issue price according to the terms set by the General Meeting, within a limit of 10% of the capital per year, suspension during public offering period.

25. Delegation of powers to be granted to the Board of Directors to issue ordinary shares, giving, as necessary, access to ordinary shares and/or to the allocation of debt securities and/or securities giving access to ordinary shares, without pre-emptive rights and/or in consideration of securities reserved for categories of persons with certain characteristics, duration of the authorization, maximum par value amount of the capital increase, issue price, option to limit the total amount of subscriptions or redistribute non-subscribed securities, suspension during public offering period.

26. Authorization to increase the total amount of issues in the event of excess demand, suspension during public offering period;

27. Delegation of powers to be granted to the Board of Directors to increase the share capital by means of the issue of ordinary shares and/or securities giving access to capital, up to the limit of 10% of the capital with a view to compensating contributions in kind of equity securities or securities giving access to the capital, duration of the delegation, suspension during public offering period.

28. Overall limitation of the maximum amounts of delegations envisaged under the Twenty-First, Twenty-Second, Twenty-Third, Twenty-Fifth and Twenty-Seventh Resolutions of this Meeting.
29. Delegation of powers to be granted to the Board of Directors to issue stock warrants (BSA), subscription and/or acquisition of new and/or existing stock warrants (BSAANE) and/or subscription and/or acquisition of new and/or existing redeemable stock warrants (BSAAR) without pre-emptive rights, reserved for a category of persons, maximum par value of the capital increase, duration of the delegation, exercise price, suspension during public offering period.

30. Authorization given to the Board of Directors to allocate free existing and/or future shares to salaried employees and/or certain corporate officers of the Company or affiliated companies, shareholder waiver of their pre-emptive rights, duration of the authorization, maximum amount, duration of vesting periods, specifically in case of disability and holding periods.

31. Authorization given to the Board of Directors to grant stock subscription and/or purchase options to members of salaried employees and/or certain corporate officers of the Company or affiliated companies, shareholder waiver of their pre-emptive rights, duration of the authorization, maximum amount, exercise price, maximum term of the option.

32. Delegation of powers to be granted to the Board of Directors to increase capital through the issue of shares of commons stock and/or securities giving rights to equity, without pre-emptive subscription right, in favor of the members of a company savings plan, pursuant to Articles L. 3332-18 et seq. of the Labor Code, duration of the delegation, maximum nominal amount of the capital increase, issue price, possibility of allotting free shares pursuant to Article L. 3332-21 of the Labor Code.

33. Alignment of the By-laws.

34. Introduction of a casting vote in the favor of the Chairman and amendment of Article 11 of the By-laws.

35. Powers to complete formalities.

*****

Terms and Conditions of Participation

The Shareholders’ Meeting is open to all shareholders regardless of the number of shares they hold.

The only shareholders who may participate in the Shareholders’ Meeting are those who can demonstrate that they hold a registered account of shares in their name or in the name of the intermediary registered for their account on the second business day preceding the Shareholders’ Meeting, in this case on June 20, 2018, at midnight Paris time:
- either in the registered share accounts kept by the company,
- or in the bearer share accounts kept by the authorized intermediate.

For registered shareholders, simply registering in a share account according to the terms set out above allows them to participate in the Shareholders’ Meeting.

For bearer shareholders, the registration of the shares in the bearer share accounts is established by a shareholding certificate issued by the bookkeeper. To participate in the Shareholders’ Meeting, this shareholding certificate must be sent by the bookkeeper to Société Générale - Shareholders’ Meeting Department - 32, rue du Champ de Tir - CS30812 - 44 308 Nantes Cédex 3 in order to obtain an admission card. Alternatively, the certification may be presented on the day of the Shareholders’ Meeting by shareholders who have not received their admission card.
Shareholders who are unable to personally attend the Shareholders’ Meeting may choose one of the following options:

a) Grant proxy to the person of their choice under the terms set out in Article L. 225-106 of the French Commercial Code;

b) Send a form of proxy to the company without indicating a proxy;

c) Vote by mail.

From the twenty-first day preceding the Shareholders’ Meeting, the single form for voting by mail or by proxy is available online on the Company’s website (www.dbv-technologies.com).

Bearer shareholders may send a written request to Société Générale to send them this form. Any requests received will be granted no later than six days before the Shareholders’ Meeting.

This form must be returned along with the bearer shareholder’s shareholding certificate. The postal vote form must be received by Société Générale’s Shareholders’ Meeting Department by June 18, 2018.

Shareholders who designate a proxy may provide notification of this delegation by e-mailing a signed, scanned copy of the form along with a photocopy of both sides of their ID card and, if applicable, of their shareholding certificate, to investors@dbv-technologies.com, or by faxing these documents to +33 (0)1.43.26.10.83. A proxy that is granted may also be revoked by the same procedures.

Shareholders who requested that items or draft resolutions be included on the agenda must send to the Company, marked for the attention of Legal Department, a new certificate of ownership for the same accounts, by midnight, Paris time, of the second business day preceding Shareholders’ Meeting.

The preparatory documents for the Shareholders’ Meeting specified in Article R. 225-73-1 of the French Commercial Code are available online on the Company’s website (www.dbv-technologies.com) for the twenty-one days preceding the Meeting.

Note that the full text of the documents to be presented at the Meeting in accordance with, in particular, Articles L. 225-115 and R. 225-83 of the French Commercial Code are available at the Company’s registered office as well as online on the Company’s website (www.dbv-technologies.com).

In accordance with Article R. 225-84 of the French Commercial Code, any shareholder may submit, to the Chairman of the Company’s Board of Directors, questions in writing until the fourth business day preceding the date of the Shareholders’ Meeting, in this case until June 18, 2018. Such written questions must be sent either by registered mail including a receipt confirmation form, addressed to the registered office, or electronically to the following address: investors@dbv-technologies.com or by fax to +33 (0)1.43.26.10.83. They must be accompanied by a certificate of account registration.

The Board of Directors